Swiss pharmaceutical industry faces potential 195 billion franc loss

A study commissioned by the Swiss industry association Interpharma warns that United States pharmaceutical policies could lead to massive economic losses for Switzerland. Conducted by BAK Economics, the analysis examines the potential impact of relocating production capacities to the US and new US pricing strategies.

In a structural break scenario, the cumulative loss in gross value added could reach 194.5 billion Swiss francs by 2040, representing approximately 22.4% of Switzerland's current economic output. Even in a base scenario, the growth of the Swiss pharmaceutical industry is projected to slow from an average of 12.8% annually (2015–2025) to 6.9% between 2025 and 2040.

The study highlights the 'Most-Favored-Nation' approach—where the US seeks to link its drug prices to those of other industrialized nations—as a critical factor. The researchers note that the most significant losses may stem from indirect consequences rather than direct price reductions in the US market.